Cargando…
HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non–small cell lung cancer
HDAC3 is one of the main targets of histone deacetylase (HDAC) inhibitors in clinical development as cancer therapies, yet the in vivo role of HDAC3 in solid tumors is unknown. We identified a critical role for HDAC3 in Kras-mutant lung cancer. Using genetically engineered mouse models (GEMMs), we f...
Autores principales: | Eichner, Lillian J., Curtis, Stephanie D., Brun, Sonja N., McGuire, Caroline K., Gushterova, Irena, Baumgart, Joshua T., Trefts, Elijah, Ross, Debbie S., Rymoff, Tammy J., Shaw, Reuben J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022903/ https://www.ncbi.nlm.nih.gov/pubmed/36930718 http://dx.doi.org/10.1126/sciadv.add3243 |
Ejemplares similares
-
Progressive alterations in amino acid and lipid metabolism correlate with peripheral neuropathy in Polg(D257A) mice
por: Lim, Esther W., et al.
Publicado: (2021) -
Circadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer
por: Pariollaud, Marie, et al.
Publicado: (2022) -
Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2022) -
Therapeutic KRAS(G12C) inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers
por: Mugarza, Edurne, et al.
Publicado: (2022) -
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
por: Mohanty, Atish, et al.
Publicado: (2023)